ViaCyte Raises $80M In Series D Funding
socalTECH
NOVEMBER 30, 2018
San Diego-based biotech startup ViaCyte , which is developing human cell therapy for treating diabetes, says it has raised $80M in a Series D funding round. The funding was led by Bain Capital Life Sciences, and also included TPG, RA Capital Management, Sanderling Ventures, plus angels. According to the company, the funding will go to advance its stem cell-derived islet replacement therapies, which are aimed at curing patients with type 1 diabetes, and also treat patients with type 2 diabetes wh
Let's personalize your content